Ipswich and East Suffolk CCG
North East Essex CCG
East Suffolk and North East Essex NHS Foundation Trust
3 Respiratory system
Inhalers
The following acronyms may be mentioned in this section in reference to inhalers
- MDI- Metered dose inhaler
- DPI- Dry powder inhaler
- BAA- Breath actuated aerosol
- ICS- Inhaled corticosteroid
- SABA- Short-acting bronchodilator
- LABA- Long-acting bronchodilator
- SAMA- Short-acting muscarinic
- LAMA - Long-acting muscarinic
Local guidance
Asthma
NEECCG Asthma plan (Asthma UK)
Joint Asthma quick reference guide - adults
Asthma quick reference guide – children (5yrs-12yrs)
Asthma quick reference guide – children (over 12yrs)
Asthma quick reference guide – children (under 5yrs)
Asthma step down guidance - adults
COPD
Joint COPD Quick Reference Guide
NEECCG COPD patient passportOther documents
03-07 Mucolytics
| Carbocisteine |
|
Formulary
|
Joint guidanceStepping down guidancePlease see below for guidance on stepping down carbocisteine for primary and secondary care Should be stopped if there is no benefit after a 4 week trial |
 IESCCG Primary care- Carbocisteine step down  IHT- Therapeutic Substitution Register  NEECCG Primary care- Carbocisteine step down |
|
| Lumacaftor + Ivacaftor Orkambi® |
|
Non Formulary
|
|
NICE TA398: Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation |
|
|
Links
- IESCCG Primary care- Carbocisteine step down
- IHT- Therapeutic Substitution Register
- NEECCG Primary care- Carbocisteine step down
- NICE CG101: COPD guideline
- NICE TA10: Asthma inhaler devices (children under 5)
- NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation
- NICE TA38: Asthma inhaler devices (older children)
- NICE TA398: Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation